A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease

NCT02151526 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Beta-Thalassemia Major
Sickle Cell Disease

Interventions

DRUG: LentiGlobin BB305 Drug Product

Sponsor

Genetix Biotherapeutics Inc.